(Q34186583)

31 July 2017

1 reference

title

Salvage therapy for refractory or relapsed acute lymphocytic leukemia (English)

1 reference

31 July 2017

0 references

1 reference

Garcia-Manero G

1

1 reference

PubMed ID

11253606

31 July 2017

Thomas DA

series ordinal

2

1 reference

31 July 2017

1 February 2001

1 reference

Hematology / Oncology Clinics of North America

31 July 2017

1 reference

31 July 2017

15

1 reference

31 July 2017

1

1 reference

31 July 2017

163-205

1 reference

Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Sequential combination of high dose ARA-C (HiDAC) and asparaginase (ASP) for the treatment of advanced acute leukemia and lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Role of BCL-2 and cell cycle regulatory proteins for corticosensitivity assessment in childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

A phase II study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Bone marrow transplantation for acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Intensive retreatment of adults and children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Second allogeneic bone marrow transplantation in acute leukemia: a multicenter study from the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Successful reinduction of patients with acute lymphoblastic leukemia who relapse following bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Chemotherapy versus transplantation in acute leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Autologous bone marrow transplantation in acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Mini-allografts: ongoing trials in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Adult acute lymphoblastic leukemia at relapse. Cytogenetic, immunophenotypic, and molecular changes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Acute lymphoblastic leukemia. A comprehensive review with emphasis on biology and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Phase I study of liposomal daunorubicin in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Promising approaches in acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

FLAG-idarubicin and allogeneic stem cell transplantation for Ph-positive ALL beyond first remission

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Transient complete remission of acute lymphoblastic leukemia in relapse after allogeneic bone marrow transplantation induced by donor leukocyte transfusions

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Treatment of relapsed or refractory adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

High expression of bcl-2 is the rule in acute lymphoblastic leukemia, except in Burkitt subtype at presentation, and is not correlated with the prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse--the Children's Cancer Group Experience

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP experience. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Associazione Italiana Ematologìa ed Ocologia Pediatrica

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R-87 protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Autologous bone marrow transplantation for high risk acute lymphoblastic leukemia: clinical relevance of ex vivo bone marrow purging with monoclonal antibodies and complement

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Transplantation of anergic histoincompatible bone marrow allografts

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

BCL-2 expression in childhood leukemia versus spontaneous apoptosis, drug induced apoptosis, and in vitro drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

BONE-MARROW TRANSPLANTATION IN HIGH-RISK ACUTE LYMPHOBLASTIC LEUKAEMIA IN FIRST AND SECOND REMISSION

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

L-asparaginase and PEG asparaginase--past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

A phase II study of continuous infusion of trimetrexate in patients with refractory acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

The proto-oncogene Bcl-2 and its role in regulating apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Relapse of leukemia and lymphoma after marrow transplant: a review of cases with extramedullary relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Mitoxantrone and continuous infusion of cytosine arabinoside in refractory and relapsed acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Autologous bone marrow transplantation with monoclonal antibody purged marrow for children with acute lymphoblastic leukemia in second remission. Spanish Working Party for BMT in Children

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Treatment of refractory and relapsed adult acute leukemia using a uniform chemotherapy protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Treatment of adult patients with acute lymphocytic leukemia in relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Autologous Transplantation with CD52 Monoclonal Antibody-Purged Marrow for Acute Lymphoblastic Leukemia: Long-Term Follow-Up

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Systemic high-dose ara-C for the treatment of meningeal leukemia in adult acute lymphoblastic leukemia and non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

High-dose methotrexate for the remission induction of refractory adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Relationship between leukemic cell retention of cytosine arabinoside triphosphate and the duration of remission in patients with acute non-lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

1 reference

7 January 2021

Acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Refractory acute lymphocytic leukemia: response to aclacinomycin A and VP-16-213.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Outcomes among 562 recipients of placental-blood transplants from unrelated donors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Aggressive chemotherapy for acute leukemia relapsed after transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Therapy of refractory adult acute lymphoblastic leukemia with vincristine and prednisone plus tandem methotrexate and L-asparaginase. Results of a Cancer and Leukemia Group B Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

FLAG (fludarabine, cytarabine, G-CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: in vitro and in vivo effects

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Modulation of cIAP-1 by novel antitubulin agents when combined with bryostatin 1 results in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Allogeneic bone marrow transplantation for acute lymphoblastic leukaemia: risk factors and clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Short-term intensive treatment (V.A.A.P.) of adult acute lymphoblastic leukemia and lymphoblastic lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Combination chemotherapy for haematological relapse in adult acute lymphoblastic leukaemia (ALL)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970204-5

7 January 2021

10.1016/S0889-8588(05)70204-5

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11253606